BACKGROUND Tertiary lymphoid structures (TLSs) are organized aggregates of immune
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …

The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …

Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a
promising approach for cancer treatment in recent years due to the critical roles of the TME …

Abstract The international American Joint Committee on Cancer/Union for International
Cancer Control (AJCC/UICC) tumour-node-metastasis (TNM) staging system provides the …

In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …

Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50
histological subtypes,. The clinical presentation of patients with different subtypes is often …

PD-1 blockade has transformed the management of advanced clear cell renal cell
carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely …

The past decades have witnessed hyperthermia therapy (HTT) as an emerging strategy
against malignant tumors. Nanomaterial‐based photothermal therapy (PTT) and magnetic …

To prevent the destruction of tissues owing to excessive and/or inappropriate immune
responses, immune cells are under strict check by various regulatory mechanisms at …

Clear cell renal carcinoma (ccRCC) is a heterogeneous disease with a variable post-
surgical course. To assemble a comprehensive ccRCC tumor microenvironment (TME) …